Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Uptake of novel oral anticoagulants in Australia

- Featured Image

Clinical trials have shown that novel oral anticoagulants (NOACs) are as efficacious as warfarin in reducing the risk of stroke in patients with atrial fibrillation.13 However, concerns regarding efficacy and safety in real-world populations remain, particularly in patients aged 75 years and older and those with comorbid conditions.4 Three NOACs — dabigatran, rivaroxaban and apixaban — were listed by the Pharmaceutical Benefits Scheme in 2013, but there is little information about their uptake in clinical practice in Australia.

We conducted a retrospective observational study to examine overall use and initiation of oral anticoagulants, and the characteristics of patients for whom they are prescribed. We used administrative claims data from the Australian Government Department of Veterans’ Affairs for patients who were full entitlement holders (ethics approval E010/010). Monthly rates of NOAC and warfarin use were calculated for the period 1 January 2012 – 31 August 2014, and numbers of veterans initiated each month on low-dose and high-dose NOACs were calculated for the period 1 September 2013 – 31 August 2014. Clinical characteristics of new users of NOACs or warfarin (no use of warfarin in the previous 12 months) were compared using χ2 or Wilcoxon rank sum tests.

email